Abstract
The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in construction of YFV17D/LASV-GPC recombinant virus. The virus was replication-competent and processed the LASV-GPC in cell cultures. The recombinant replicated poorly in guinea pigs but still elicited specific antibodies against LASV and YFV17D antigens. A single subcutaneous injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. This study demonstrates the potential to develop an YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Glycoproteins / genetics
-
Glycoproteins / metabolism*
-
Guinea Pigs
-
Humans
-
Lassa Fever / prevention & control*
-
Lassa virus / genetics
-
Lassa virus / immunology
-
Lassa virus / metabolism*
-
Vaccines, Synthetic* / administration & dosage
-
Vaccines, Synthetic* / genetics
-
Vaccines, Synthetic* / metabolism
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / genetics
-
Viral Vaccines / metabolism
-
Yellow Fever / prevention & control
-
Yellow Fever Vaccine* / administration & dosage
-
Yellow Fever Vaccine* / genetics
-
Yellow Fever Vaccine* / metabolism
-
Yellow fever virus / immunology
Substances
-
Glycoproteins
-
Vaccines, Synthetic
-
Viral Vaccines
-
Yellow Fever Vaccine